Kane Biotech passes regulatory "milestones"

Executive Summary

• Kane Biotech Inc. has received FDA 510(k) clearance for its Revyve™ Antimicrobial Skin and Wound Cleanser, a significant regulatory milestone for its wound care platform.
• The company has expanded its ISO 13485:2016 certification under the Medical Device Single Audit Program (MDSAP) to include distribution and wound cleansers, aligning with the FDA's new Quality Management System Regulation (QMSR).
• Manufacturing technology transfer and scale-up for the cleanser are planned for later in 2026, with sales activities expected shortly thereafter.

Key Details

• Product: Revyve™ Antimicrobial Skin and Wound Cleanser.
• Regulatory Status: Received U.S. Food and Drug Administration (FDA) 510(k) clearance.
• Intended Use: Mechanical cleansing, moistening, debriding, and removal of foreign material (including micro-organisms and debris) from acute and chronic dermal lesions.
• Target Conditions: Stage I-IV pressure ulcers, venous ulcers, leg ulcers, diabetic foot ulcers, postsurgical wounds, first and superficial second-degree burns, grafted/donor sites, minor cuts, minor burns, and superficial abrasions.
• Additional Function: Intended for moistening absorbent wound dressings.
• Technology Platform: Designed to address wound bacteria and biofilms, which are major contributors to delayed healing and antibiotic resistance.
• Commercial Timeline: Manufacturing technology transfer and scale-up planned for later in 2026; sales activities planned shortly thereafter.
• Certification Expansion: Expanded ISO 13485:2016 certification under MDSAP to include distribution and wound cleansers.
• Existing Certifications: Non-sterile antimicrobial wound dressings (Revyve™ Antimicrobial Wound Gel and Revyve™ Antimicrobial Wound Gel Spray).
• Regulatory Alignment: Expansion aligns with the FDA's new Quality Management System Regulation (QMSR), which came into effect in February 2026, harmonizing U.S. requirements with ISO 13485.
• Strategic Impact: Supports ability to pursue regulatory approvals across multiple jurisdictions and demonstrates investment in quality systems, compliance, and operational readiness.

Notable Quotes

• "These achievements reflect Kane's disciplined approach to advancing its wound care portfolio," said Lori Christofalos, chief quality officer. "ISO 13485 and MDSAP compliance strengthens trust among health-care providers and patients, and ensures Kane is aligned with evolving regulatory expectations."